(Q38529445)

3 September 2017

1 reference

title

Why have ovarian cancer mortality rates declined? Part II. Case-fatality (English)

1 reference

3 September 2017

1 reference

4

Steven A Narod

1 reference

3 September 2017

Victoria Sopik

1

1 reference

3 September 2017

Javaid Iqbal

series ordinal

2

1 reference

3 September 2017

Barry Rosen

series ordinal

3

1 reference

3 September 2017

language of work or name

English

0 references

publication date

13 June 2015

1 reference

3 September 2017

1 reference

3 September 2017

138

1 reference

3 September 2017

3

1 reference

3 September 2017

750-756

1 reference

Why have ovarian cancer mortality rates declined? Part I. Incidence

3 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Five year survival rates can mislead

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

State of the science in ovarian cancer quality of life research: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Maintenance chemotherapy in the management of epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Have we given up on a cure for ovarian cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining 'optimal' residual disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

A framework for a personalized surgical approach to ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo Clinic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Radical surgery in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Predicting surgical outcome in patients with International Federation of Gynecology and Obstetrics stage III or IV ovarian cancer using computed tomography: a systematic review of prediction models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Ovarian cancer, version 2.2013.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Clinical pharmacology of intraperitoneal cisplatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Survival benefit of adding Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at the different time-points of treatment of ovarian cancer: review of evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER-O registry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Diffusion of Intraperitoneal Chemotherapy in Women with Advanced Ovarian Cancer in Community Settings 2003-2008: The Effect of the NCI Clinical Recommendation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Intraperitoneal chemotherapy among women in the Medicare population with epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

Why have ovarian cancer mortality rates declined? Part III. Prospects for the future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.016

10.1016/J.YGYNO.2015.06.016

7 January 2021

Identifiers

DOI

1 reference

3 September 2017

1 reference